Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
NCT03580967 · Todd Doyle · PHASE4 · withdrawn · last registry update 2022-11-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID-19 Pandemic interfered with Pt recruitment” | – | Registry record, Todd Doyle |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-28Results posted on the registry: University of California, Los Angeles, Aripiprazole Lauroxil + ARI-ORAL (NCT04203056)
- 2023-11-28Also stopped (terminated): University of California, Los Angeles, Aripiprazole Lauroxil + ARI-ORAL (NCT04203056)
- 2023-11-18Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Aripiprazole + Aripiprazole (NCT04030143)
- 2023-11-15Results posted on the registry: Northwell Health, Aripiprazole + Fluoxetine (NCT02357849)
- 2023-11-15Also stopped (terminated): Northwell Health, Aripiprazole + Fluoxetine (NCT02357849)
- 2023-11-14Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole + Brexpiprazole (NCT03594123)
- 2023-10-12Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole + Antidepressant therapy (NCT03538691)
- 2023-09-18Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole (NCT03548584)
- 2023-09-06Phase 3 first posted: Federico II University, Vortioxetine 20Mg Tab + Paroxetine 20 Mg Oral Tablet (NCT06025474)
- 2023-06-15Results posted on the registry: Johns Hopkins Bloomberg School of Public Health, Buspirone + Placebo (NCT03587142)
- 2023-04-21Phase 3 first posted: Qilu Pharmaceutical (Hainan) Co., Ltd., Amisulpride + Amisulpride Placebo (NCT05822713)
- 2023-04-18Phase 3 first posted: Guy Boeckxstaens, Ebastine + Duspatalin (NCT05815602)
- 2023-02-02Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., OPDC-34712 + Placebo (NCT01074294)
- 2023-01-30Also stopped (withdrawn): Otsuka Pharmaceutical Development & Commercialization, Inc., Brexpiprazole (NCT05504486)
- 2023-01-05Results posted on the registry: H. Lundbeck A/S, Vortioxetine + Placebo (NCT05014919)
- 2023-01-05Also stopped (terminated): H. Lundbeck A/S, Vortioxetine + Placebo (NCT05014919)
- 2022-12-28Results posted on the registry: H. Lundbeck A/S, Vortioxetine (NCT02871297)
- 2022-12-28Also stopped (terminated): H. Lundbeck A/S, Vortioxetine (NCT02871297)
- 2022-09-22Results posted on the registry: H. Lundbeck A/S, Vortioxetine 10 mg/day + Vortioxetine 20 mg/day (NCT02709655)
- 2022-09-19Phase 3 first posted: Acacia Pharma Ltd, Amisulpride Injection + Dexamethasone (NCT05546359)
- 2022-09-14Also stopped (withdrawn): Shanghai Mental Health Center, Aripiprazole (NCT02955654)
- 2022-09-07Results posted on the registry: Denovo Biopharma LLC, LY2140023 + Aripiprazole (NCT01328093)
- 2022-09-07Also stopped (terminated): Denovo Biopharma LLC, LY2140023 + Aripiprazole (NCT01328093)
- 2022-09-01Results posted on the registry: Denovo Biopharma LLC, LY2140023 + aripiprazole (NCT00845026)
- 2022-08-16Results posted on the registry: Janssen Research & Development, LLC, JNJ-42847922 + Placebo Matching to JNJ-42847922 (NCT03321526)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision